Table 2.

Characteristics of subjects in the gemfibrozil arm with and without new CVD events (non-fatal MI, CHD death and stroke) in the 5.1 year follow up.

Variable	CVD (+)	CVD (-)
	N=168	N=586
Age (year)	64.8 ± 7.0	63.7 ± 7.5
BMI (kg/m2)	29.0 ±5.0	29.1 ± 5.0
Hypertension (%)	63.0	54.9
Diabetes (%)	38.7	33.3
Smoking (%)	23.8	17.7
Total-C	169.2 ± 27.5	166.2 ± 27.8
LDL-C	113.0 ± 24.5	111.2 ± 25.4
TG†	119.2 ± 69.9	106.8 ± 54.8
HDL Variables
HDL-C	32.5 ± 6.0	33.6 ± 6.4
Apolipoprotein A-I	107.5 ± 16.9	110.2 ± 18.0
Preβ-1	13.3 ± 7.0	11.6 ± 6.1*
Preβ-2	2.0 ± 1.3	2.3 ± 1.4**
α-1	7.9 ± 4.3	8.8 ± 4.9**
α-2	28.9 ± 8.2	31.4 ± 8.5*
α-3	41.7 ± 9.1	41.3 ± 10.0
Preα-1	2.7 ± 2.3	2.9 ± 2.5
Preα-2	5.0 ± 2.4	5.5 ± 2.4**
Preα-3	6.1 ± 2.4	6.5 ± 2.5

Values are mean ± SD (mg/dl) or as indicated.

^†Statistical test performed using log transformed values.

^*p<0.01

^**p<0.05